Brightplex® is an automated workflow that takes advantage of brightfield microscopy, using standardized reagents, proprietary know-how and advanced image analysis to enable the robust analysis of combinations of up to 7 biomarkers on a single slide. The image processing component of the Brightplex® technology leverages Indica Labs’ HALO™ image analysis platform.
Brightplex® bioinformatics platform allows dedicated analysis of a complete set of data providing unpreceded information on the tumor microenvironment. Basically, specific immune cell populations can be precisely quantified and spatially localized in specific region of interest (tumor, invasive margin, stroma, parenchyma) of the tissue. When associated to clinical information, this powerful set of data are used to help understanding drug’s mechanism of action and drug resistance.
Together, these 2 panels provide an invaluable set of tools to analyze the immune contexture of a tumor in translational and clinical research in immuno-oncology to help overcome anti-PD-1/PD-L1 resistance in Lung cancer.
The development of Brightplex® TCE and Brightplex® MDSC was supported by the French National Research Agency (ANR) in the context of the PIONeeR project, a 5-year research program that aims to better understand, predict and overcome anti-PD-1/PD-L1 resistance in advanced lung cancer patients.